Co-Diagnostics (CODX) Stock Price, News & Analysis

Company Overview

Co-Diagnostics, Inc. is a molecular diagnostics company headquartered in Salt Lake City, Utah. The company develops and commercializes diagnostic technologies and laboratory tests designed to identify infectious diseases and other medical conditions using polymerase chain reaction (PCR) and related molecular methods.

Its core technology is the CoPrimer platform, which is intended to support the development of accurate, cost-efficient molecular diagnostic tests. Co-Diagnostics has marketed tests under the Logix Smart brand, including assays for respiratory and other infectious diseases. The company also developed molecular testing products related to COVID-19 and has pursued diagnostic applications in areas such as tuberculosis, mosquito-borne diseases, women’s health and oncology.

Co-Diagnostics was founded in 2013 and serves customers through commercial, laboratory and distribution channels in the United States and international markets. Its products are designed for use by clinical laboratories, healthcare providers and other testing organizations, with availability varying by product, regulatory authorization and geography. Dwight E. Hurst is a co-founder and has served as the company’s chief executive officer.

Key Stats

• Today's Range: $0.63 to $0.75
• 50-Day Range: $0.65 to $1.50
• 52-Week Range: $0.63 to $46.50
• Volume: 328,831 shs
• Average Volume: 364,956 shs
• Market Capitalization: $4.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $67.50
• Consensus Rating: Moderate Buy

Co-Diagnostics Stock Analysis - MarketRank™

Co-Diagnostics scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Co-Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Co-Diagnostics has a consensus price target of $67.50, representing about 10,221.1% upside from its current price of $0.65.

Amount of Analyst Coverage

Co-Diagnostics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Co-Diagnostics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Co-Diagnostics is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Co-Diagnostics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.14% of the float of Co-Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Co-Diagnostics has a short interest ratio ("days to cover") of 1.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Co-Diagnostics has recently increased by 37.37%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Co-Diagnostics does not currently pay a dividend.

Dividend Growth

Co-Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Co-Diagnostics this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Co-Diagnostics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.30% of the stock of Co-Diagnostics is held by insiders.

Percentage Held by Institutions

14.99% of the stock of Co-Diagnostics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/18/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CODX
• CIK: 1692415
• Web: www.codiagnostics.com
• Phone: (801) 438-1036
• Fax: N/A
• Employees: 115
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Co-Diagnostics: $67.50
• High Price Target: $90.00
• Low Price Target: $45.00
• Potential Upside/Downside: +10,221.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($10.32)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$46.90 million
• Net Margins: -6,531.77%
• Pretax Margin: -6,756.77%
• Return on Equity: -210.99%
• Return on Assets: -174.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.81
• Quick Ratio: 1.52

Sales & Book Value

• Annual Sales: $721.39 thousand
• Price / Sales: 6.33
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.14 per share
• Price / Book: 0.07

Miscellaneous

• Outstanding Shares: 6,981,000
• Free Float: 6,820,000
• Market Cap: $4.57 million
• Optionable: No Data
• Beta: 2.90